Safety and efficacy of ipilimumab to treat advanced melanoma in the setting of liver transplantation
Open accessAbstract
Ipilimumab is a first-in-class immunological checkpoint blockade agent and monoclonal antibody against Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) that has demonstrated survival benefit and durable responses in patients with metastatic melanoma. To date, solid organ transplant recipients have been excluded from clinical trials with cancer immunotherapies on the basis of their concurrent treatment with immunosuppressive agents. We present the first case to our knowledge of a patient with advanced cutaneous melanoma receiving ipilimumab status post orthotopic liver transplantation with a partial response. Transaminitis was observed 4 months after administration of ipilimumab that resolved with close observation. No evidence of graft rejection has been observed to date. This case advocates for further investigation of the safety and efficacy of cancer immunotherapies in solid organ transplant recipients.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Several transplant patients experienced a tumor response without rejection when their immunosuppressive regimen contained sirolimus.
“Interestingly, several transplant patients experienced a tumor response without rejection when their immunosuppressive regimen contained sirolimus.165,169,170”
From Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: Review of the literature and personalized risk-based prevention strategy (2020) · cites this paper as [169]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,314 · see citing works
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · see citing works
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496 · see citing works
Schadendorf, D., Hodi, F. S., Robert, C., Weber, J. S., Margolin, K., Hamid, O., Patt, D., Chen, T.-T., Berman, D. M., & Wolchok, J. D. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2736 · Cited by 2,141 · see citing works
Benítez, C., Londoño, M., Miquel, R., Manzia, T. M., Abraldeṣ, J. G., Lozano, J. J., Martínez‐Llordella, M., López, M., Angelico, R., Bohne, F., et al. (2013) · Hepatology · doi:10.1002/hep.26426 · Cited by 319 · see citing works
Fueyo, A. S., & Strom, T. B. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.10.059 · Cited by 236 · see citing works
Lipson, E. J., Bodell, M. A., Kraus, E. S., & Sharfman, W. H. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.2314 · Cited by 158 · see citing works
Self-citationde la Garza, R. G., Sarobe, P., Merino, J., Lasarte, J. J., D’Avola, D., Belsúe, V., Delgado, J. A., Silva, L., Iñarrairaegui, M., Sangro, B., et al. (2013) · Liver Transplantation · doi:10.1002/lt.23686 · Cited by 96 · see citing works
Malignant Melanoma in Solid Transplant Recipients
Brewer, J. D. (2011) · Archives of Dermatology · doi:10.1001/archdermatol.2011.159 · Cited by 93 · see citing works
Systematic review of melanoma incidence and prognosis in solid organ transplant recipients
Dahlke, E. J., Murray, C., Kitchen, J., & Chan, A. (2014) · Transplantation Research · doi:10.1186/2047-1440-3-10 · Cited by 80 · see citing works
Dillon, P. M., Thomas, N. E., Sharpless, N. E., & Collichio, F. A. (2009) · Medical Oncology · doi:10.1007/s12032-009-9348-z · Cited by 18 · see citing works
Withdrawal of immunosuppression contributing to the remission of malignant melanoma: a case report.
Hodi, F. S., Granter, S. R., & Antin, J. H. (2005) · PubMed · Cited by 14 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Postow, M. A., Sidlow, R., & Hellmann, M. D. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1703481 · Cited by 4,849 · see citing works
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
Naidoo, J., Page, D. B., Li, B. T., Connell, L. C., Schindler, K., Lacouture, M. E., Postow, M. A., & Wolchok, J. D. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv383 · Cited by 1,489 · see citing works
Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
Johnson, D. B., Sullivan, R. J., Ott, P. A., Carlino, M. S., Khushalani, N. I., Ye, F., Guminski, A., Puzanov, I., Lawrence, D. P., Buchbinder, E. I., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2015.4368 · Cited by 642 · see citing works
Thompson, J. A., Schneider, B. J., Brahmer, J., Andrews, S., Armand, P., Bhatia, S., Budde, L. E., Costa, L., Davies, M., Dunnington, D., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0013 · Cited by 570 · see citing works
Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference
Llovet, J. M., Villanueva, A., Marrero, J. A., Schwartz, M., Meyer, T., Galle, P. R., Lencioni, R., Greten, T. F., Kudo, M., Mandrekar, S. J., et al. (2021) · Hepatology · doi:10.1002/hep.31327 · Cited by 413 · see citing works
Immune checkpoint inhibitors in challenging populations
Johnson, D. B., Sullivan, R. J., & Menzies, A. M. (2017) · Cancer · doi:10.1002/cncr.30642 · Cited by 339 · see citing works
Immunotherapy of Hepatocellular Carcinoma: Facts and Hopes
Iñarrairaegui, M., Melero, I., & Sangro, B. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0289 · Cited by 235 · see citing works
Haanen, J., Ernstoff, M. S., Wang, Y., Menzies, A. M., Puzanov, I., Grivas, P., Larkin, J., Peters, S., Thompson, J. A., & Obeid, M. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.03.285 · Cited by 222 · see citing works
Liver transplantation immunology: immunosuppression, rejection, and immunomodulation
Montano-Loza, A. J., Rodríguez-Perálvarez, M. L., Pageaux, G.-P., Sanchez-Fueyo, A., & Feng, S. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.01.030 · Cited by 208 · see citing works
DeLeon, T. T., Salomao, M. A., Aqel, B. A., Sonbol, M. B., Yokoda, R. T., Ali, A. H., Moss, A. A., Mathur, A. K., Chascsa, D. M., Rakela, J., et al. (2018) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2018.07.05 · Cited by 157 · see citing works
Fisher, J., Zeitouni, N. C., Fan, W., & Samie, F. H. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.07.005 · Cited by 157 · see citing works
Kumar, V., Shinagare, A. B., Rennke, H. G., Ghai, S., Lorch, J. H., Ott, P. A., & Rahma, O. E. (2020) · The Oncologist · doi:10.1634/theoncologist.2019-0659 · Cited by 152 · see citing works
Immune Checkpoint Inhibitors in Organ Transplant Patients
Kittai, A. S., Oldham, H., Cetnar, J., & Taylor, M. (2017) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000180 · Cited by 151 · see citing works
Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanoma
Spain, L. A., Higgins, R. M., Gopalakrishnan, K., Turajlic, S., Gore, M. E., & Larkin, J. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw130 · Cited by 145 · see citing works
Liver Allograft Failure After Nivolumab Treatment—A Case Report With Systematic Literature Research
Gassmann, D., Weiler, S., Mertens, J. C., Reiner, C. S., Vrugt, B., Nägeli, M., Mangana, J., Müllhaupt, B., Jenni, F., & Misselwitz, B. (2018) · Transplantation Direct · doi:10.1097/txd.0000000000000814 · Cited by 139 · see citing works
Friend, B. D., Venick, R. S., McDiarmid, S. V., Zhou, X., Naini, B. V., Wang, H., Farmer, D. G., Busuttil, R. W., & Federman, N. C. (2017) · Pediatric Blood & Cancer · doi:10.1002/pbc.26682 · Cited by 135 · see citing works
Impact of Immune-Modulatory Drugs on Regulatory T Cell
Furukawa, A., Wisel, S. A., & Tang, Q. (2016) · Transplantation · doi:10.1097/tp.0000000000001379 · Cited by 127 · see citing works
Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors
Day, D., & Hansen, A. R. (2016) · BioDrugs · doi:10.1007/s40259-016-0204-3 · Cited by 115 · see citing works
Use of checkpoint inhibitors in liver transplant recipients
Munker, S., & Toni, E. N. D. (2018) · United European Gastroenterology Journal · doi:10.1177/2050640618774631 · Cited by 104 · see citing works
Checkpoint inhibitors in chronic kidney failure and an organ transplant recipient
Herz, S., Höfer, T., Papapanagiotou, M., Leyh, J., Meyenburg, S., Schadendorf, D., Ugurel, S., Roesch, A., Livingstone, E., Schilling, B., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.07.026 · Cited by 102 · see citing works
Renal complications of immune checkpoint blockade
Murakami, N., Motwani, S. S., & Riella, L. V. (2016) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2016.12.004 · Cited by 99 · see citing works
Krisl, J. C., & Doan, V. (2017) · American Journal of Transplantation · doi:10.1111/ajt.14238 · Cited by 100 · see citing works
Acute Severe Autoimmune Hepatitis: Corticosteroids or Liver Transplantation?
Rahim, M. N., Liberal, R., Miquel, R., Heaton, N. D., & Heneghan, M. A. (2019) · Liver Transplantation · doi:10.1002/lt.25451 · Cited by 91 · see citing works
Antitumor activity of nivolumab on hemodialysis after renal allograft rejection
Ong, M., Ibrahim, A. M., Bourassa‐Blanchette, S., Canil, C., Fairhead, T., & Knoll, G. A. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0171-8 · Cited by 81 · see citing works
Immune checkpoint blockade for organ transplant patients with advanced cancer: how far can we go?
De Bruyn, P., Van Gestel, D., Ost, P., Kruse, V., Brochez, L., Van Vlierberghe, H., Devresse, A., del Marmol, V., Le Moine, A., & Aspeslagh, S. (2019) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000505 · Cited by 79 · see citing works
Au, K. P., & Chok, K. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i45.5081 · Cited by 79 · see citing works
Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction
Kanz, B. A., Pollack, M. H., Johnpulle, R., Puzanov, I., Horn, L., Morgans, A., Sosman, J. A., Rapisuwon, S., Conry, R. M., Eroglu, Z., et al. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0166-5 · Cited by 75 · see citing works
Systematic Review of the Safety of Immune Checkpoint Inhibitors Among Kidney Transplant Patients
Manohar, S., Thongprayoon, C., Cheungpasitporn, W., Markovic, S. N., & Herrmann, S. M. (2019) · Kidney International Reports · doi:10.1016/j.ekir.2019.11.015 · Cited by 74 · see citing works
O'Kane, G. M., Labbé, C., Doherty, M. K., Young, K., Albaba, H., & Leighl, N. B. (2016) · The Oncologist · doi:10.1634/theoncologist.2016-0164 · Cited by 72 · see citing works
Aguirre, L. E., Guzman, M. E., Lopes, G., & Hurley, J. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0195 · Cited by 68 · see citing works
A review of serious adverse effects under treatment with checkpoint inhibitors
Heinzerling, L., & Goldinger, S. M. (2017) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000358 · Cited by 67 · see citing works
Kuo, J. C.-Y., Lilly, L., & Hogg, D. (2017) · Melanoma Research · doi:10.1097/cmr.0000000000000410 · Cited by 65 · see citing works
Kayali, S., Pasta, A., Torres, M. C. P., Jaffe, A., Strazzabosco, M., Marenco, S., & Giannini, E. G. (2022) · Liver International · doi:10.1111/liv.15419 · Cited by 60 · see citing works
Immunotherapy and Liver Transplantation: A Narrative Review of Basic and Clinical Data
Wassmer, C., Hajji, S. E., Papazarkadas, X., Compagnon, P., Tabrizian, P., Lacotte, S., & Toso, C. (2023) · Cancers · doi:10.3390/cancers15184574 · Cited by 52 · see citing works
Chae, Y. K., Galvez, C., Anker, J. F., Iams, W. T., & Bhave, M. A. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.12.004 · Cited by 50 · see citing works
Abdelrahim, M., Esmail, A., Saharia, A., Abudayyeh, A., Abdel‐Wahab, N., Diab, A. K., Murakami, N., Kaseb, A. O., Chang, J. C., Gaber, A. O., et al. (2022) · Cancers · doi:10.3390/cancers14071760 · Cited by 47 · see citing works
Acute liver graft rejection after ipilimumab therapy
Dueland, S., Guren, T. K., Boberg, K. M., Reims, H. M., Grzyb, K., Aamdal, S., Julsrud, L., & Line, P. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx281 · Cited by 46 · see citing works
Ipilimumab for the treatment of advanced melanoma in six kidney transplant patients
Zehou, O., Leibler, C., Arnault, J., Sayegh, J., Montaudié, H., Rémy, P., Glotz, D., Cordonnier, C., Martin, L., & Lebbé, C. (2018) · American Journal of Transplantation · doi:10.1111/ajt.15071 · Cited by 45 · see citing works
Liver graft rejection following immune checkpoint inhibitors treatment: a review
Hu, B., Yang, X., & Sang, X. (2019) · Medical Oncology · doi:10.1007/s12032-019-1316-7 · Cited by 44 · see citing works
The Bad and the Good News on Cancer Immunotherapy: Implications for Organ Transplant Recipients
Maggiore, U., & Pascual, J. (2016) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2016.08.002 · Cited by 43 · see citing works
Immune checkpoint inhibitors for solid organ transplant recipients: clinical updates
Kawashima, S., Joachim, K., Abdelrahim, M., Abudayyeh, A., Jhaveri, K. D., & Murakami, N. (2022) · Korean Journal of Transplantation · doi:10.4285/kjt.22.0013 · Cited by 39 · see citing works
Cutaneous squamous cell carcinoma in the organ transplant recipient
Bibee, K., Swartz, A., Sridharan, S., Kürten, C. H. L., Wessel, C. B., Skinner, H. D., & Zandberg, D. P. (2020) · Oral Oncology · doi:10.1016/j.oraloncology.2019.104562 · Cited by 37 · see citing works
Immunotherapy after liver transplantation: Where are we now?
Au, K. P., & Chok, K. (2021) · World Journal of Gastrointestinal Surgery · doi:10.4240/wjgs.v13.i10.1267 · Cited by 37 · see citing works
Immune Checkpoint Inhibition in Non-Melanoma Skin Cancer: A Review of Current Evidence
Stonesifer, C. J., Djavid, A. R., Grimes, J. M., Khaleel, A. E., Soliman, Y. S., Maisel-Campbell, A. L., Garcia-Saleem, T. J., Geskin, L. J., & Carvajal, R. D. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.734354 · Cited by 36 · see citing works
Self-citationSpecenier, P. M. (2016) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2016.1211936 · Cited by 37 · see citing works
Winkler, J. K., Gutzmer, R., Bender, C., Lang, N., Zeier, M. G., Enk, A., & Hassel, J. C. (2017) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000188 · Cited by 35 · see citing works
Biomarkers in hepatocellular carcinoma: an overview
Juárez-Hernández, E., Motola‐Kuba, D., Chávez-Tapia, N. C., Uribe, M., & Barbero-Becerra, V. J. (2017) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2017.1311785 · Cited by 34 · see citing works
Delyon, J., Zuber, J., Dorent, R., Poujol‐Robert, A., Péraldi, M., Anglicheau, D., & Lebbé, C. (2020) · Transplantation · doi:10.1097/tp.0000000000003292 · Cited by 34 · see citing works
Immune checkpoint blockade for organ-transplant recipients with cancer: A review
Rünger, A., Schadendorf, D., Hauschild, A., & Gebhardt, C. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.08.010 · Cited by 34 · see citing works
Pandey, A., & Cohen, D. J. (2020) · Immunotherapy · doi:10.2217/imt-2020-0014 · Cited by 33 · see citing works
Schvartsman, G., Perez, K., Flynn, J. E., Myers, J. N., & Tawbi, H. A. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0250-5 · Cited by 31 · see citing works
Cui, X., Yan, C., Xu, Y., Li, D., Guo, M., Sun, L., & Zhu, Z. (2022) · Cancer Medicine · doi:10.1002/cam4.5394 · Cited by 29 · see citing works
The role of calcium hydroxylapatite (Radiesse) in nonsurgical aesthetic rejuvenation.
Lizzul, P. F., & Narurkar, V. A. (2010) · PubMed · Cited by 30 · see citing works
New Systemic Treatments in Advanced Hepatocellular Carcinoma
Sanduzzi‐Zamparelli, M., Díaz‐González, Á., & Reig, M. (2018) · Liver Transplantation · doi:10.1002/lt.25354 · Cited by 28 · see citing works
Jiang, J., Huang, H., Chen, R., Lin, Y., & Ling, Q. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1092401 · Cited by 28 · see citing works
Immune Checkpoint Inhibitors in the Cancer Patient with An Organ Transplant
Wanchoo, R., Riella, L. V., Uppal, N. N., Lopez, C. A., Nair, V. V., Devoe, C., & Jhaveri, K. D. (2017) · Journal of Onco-Nephrology · doi:10.5301/jo-n.5000006 · Cited by 26 · see citing works
Grant, M. J., DeVito, N., & Salama, A. K. S. (2018) · Melanoma Management · doi:10.2217/mmt-2018-0004 · Cited by 24 · see citing works
Cancer in Solid Organ Transplant Recipients: There Is Still Much to Learn and Do
Engels, E. A. (2017) · American Journal of Transplantation · doi:10.1111/ajt.14140 · Cited by 24 · see citing works
Qiu, J., Tang, W., & Du, C. (2020) · Current Cancer Drug Targets · doi:10.2174/1568009620666200520084415 · Cited by 24 · see citing works
Graft rejection after immune checkpoint inhibitor therapy in solid organ transplant recipients
Smedman, T. M., Line, P., Guren, T. K., & Dueland, S. (2018) · Acta Oncologica · doi:10.1080/0284186x.2018.1479069 · Cited by 24 · see citing works
Immunotherapy in liver transplantation for hepatocellular carcinoma: Pros and cons
Luo, Y., Teng, F., Fu, H. Y., & Ding, G. (2022) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v14.i1.163 · Cited by 23 · see citing works
Holistic management of hepatocellular carcinoma: The hepatologist's comprehensive playbook
Jaffe, A., Taddei, T. H., Giannini, E. G., Ilagan‐Ying, Y. C., Colombo, M., & Strazzabosco, M. (2022) · Liver International · doi:10.1111/liv.15432 · Cited by 23 · see citing works
Zhang, P., Zhu, G., Li, L., Lai, G., Wang, Z., Sun, C., Xia, W., & Wu, L. (2022) · Transplantation Reviews · doi:10.1016/j.trre.2022.100712 · Cited by 22 · see citing works
Tolerability of immune checkpoint inhibition cancer therapy in a cardiac transplant patient
Gastman, B., & Ernstoff, M. S. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw293 · Cited by 21 · see citing works
Abboud, K., Umoru, G., Esmail, A., Abudayyeh, A., Murakami, N., Al-Shamsi, H. O., Javle, M. M., Saharia, A., Connor, A. A., Kodali, S., et al. (2023) · Cancers · doi:10.3390/cancers15051433 · Cited by 20 · see citing works
Chen, J. A., Esteghamat, N., Kim, E. J.-H., García, G., Gong, J., Fakih, M., Bold, R. J., & Cho, M. T. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.7328 · Cited by 18 · see citing works
Immune checkpoint inhibitors in liver transplant recipients - a review of current literature
Yin, C., Baba, T., He, A. R., & Smith, C. I. (2021) · Hepatoma Research · doi:10.20517/2394-5079.2021.11 · Cited by 17 · see citing works
The safety of pembrolizumab in metastatic melanoma and rheumatoid arthritis
Puri, A., & Homsi, J. (2017) · Melanoma Research · doi:10.1097/cmr.0000000000000387 · Cited by 17 · see citing works
Gu, Y., Xu, S., Wang, Z., Yang, J., Zheng, S., Wei, Q., Liu, Z., & Xu, X. (2023) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2023.02.02 · Cited by 17 · see citing works
Babey, H., Quéré, G., Descourt, R., Calloch, R. L., Lanfranco, L., Nousbaum, J., Cornec, D., Tison, A., & CHOUAID, C. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1499468 · Cited by 16 · see citing works
Abdelrahim, M., Esmail, A., Divatia, M. K., Xu, J., Kodali, S., Victor, D. W., Brombosz, E. W., Connor, A. A., Saharia, A., Elaileh, A., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13113068 · Cited by 15 · see citing works
Immunotherapy in organ-transplanted cancer patients: efficacy and risk of organ rejection
Ros, J., Matos, I. G., & Martín-Liberal, J. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz129 · Cited by 15 · see citing works
Immunotherapy and Liver Transplantation
Tabrizian, P., Yu, A. T., Debnath, N., Myers, B., & Marron, T. U. (2023) · Surgical Clinics of North America · doi:10.1016/j.suc.2023.07.009 · Cited by 13 · see citing works
Liver Transplantation for Hepatocellular Carcinoma in the Era of Immune Checkpoint Inhibitors
Stefano, N. D., Patrono, D., Colli, F., Rizza, G., Paraluppi, G., & Romagnoli, R. (2024) · Cancers · doi:10.3390/cancers16132374 · Cited by 13 · see citing works
Immune checkpoint inhibitors in the management of malignancies in transplant recipients
Regalla, D. K. R., Williams, G. R., & Paluri, R. K. (2018) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2018-136081 · Cited by 13 · see citing works
Joo, V., Abdelhamid, K., Noto, A., Latifyan, S., Martina, F., Daoudlarian, D., Micheli, R. D., Pruijm, M. T., Peters, S., Hullin, R., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47965-3 · Cited by 13 · see citing works
Immuno-oncology for Hepatocellular Carcinoma
Armstrong, S. A., & He, A. R. (2020) · Clinics in Liver Disease · doi:10.1016/j.cld.2020.07.007 · Cited by 10 · see citing works
An analysis report on the application of immune checkpoint inhibitors after liver transplantation
Xie, M., Dang, Z.-P., Sun, X., Zhang, B., Zhang, Q., Tian, Q., Cai, J.-Z., & Rao, W. (2022) · Therapeutic Advances in Chronic Disease · doi:10.1177/20406223221099334 · Cited by 9 · see citing works
A systematic review of yttrium-90 radioembolization for unresectable liver metastases of melanoma
Jia, Z., Jiang, G., Zhu, C., Wang, K., Li, S., & Qin, X. (2017) · European Journal of Radiology · doi:10.1016/j.ejrad.2017.05.005 · Cited by 9 · see citing works
Miao, K., & Zhang, L. (2021) · Interdisciplinary Sciences Computational Life Sciences · doi:10.1007/s12539-021-00437-4 · Cited by 9 · see citing works
Weighing Up the Pros and Cons of Immune Checkpoint Inhibitors in The Treatment of Melanoma
Spain, L. A., & Larkin, J. (2016) · Immunotherapy · doi:10.2217/imt.16.6 · Cited by 9 · see citing works
Marco, L. D., Romanzi, A., Pivetti, A., Maria, N. D., Ravaioli, F., Salati, M., Villa, E., Benedetto, F. D., Magistri, P., Dominici, M., et al. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104607 · Cited by 8 · see citing works
Management of checkpoint inhibitor-associated renal toxicities
Vanoverbeke, L., & Sprangers, B. (2017) · Expert Review of Quality of Life in Cancer Care · doi:10.1080/23809000.2017.1369045 · Cited by 7 · see citing works
Role of Intrahepatic Regional Immunity in Post-Transplant Cancer Recurrence
Liu, J., Lo, C. M., & Man, K. (2021) · Engineering · doi:10.1016/j.eng.2021.11.012 · Cited by 7 · see citing works
Melanoma en pacientes receptores de un trasplante de órgano sólido
González‐Cruz, C., Ferrándiz‐Pulido, C., & García-Patos, V. (2020) · Actas Dermo-Sifiliográficas · doi:10.1016/j.ad.2020.11.005 · Cited by 7 · see citing works
Struckmeier, A., Gosau, M., & Smeets, R. (2024) · Transplantation Reviews · doi:10.1016/j.trre.2024.100882 · Cited by 6 · see citing works
Martin, S. P., Mehta, N. J., & Emamaullee, J. A. (2024) · Liver Transplantation · doi:10.1097/lvt.0000000000000350 · Cited by 6 · see citing works
Ji, S., Liu, H., Pachella, L. A., Stephenson, R. D., Groisberg, R., & Weiss, S. A. (2023) · Frontiers in Transplantation · doi:10.3389/frtra.2023.1284740 · Cited by 5 · see citing works
Vogel, A., Sterneck, M. R., Vondran, F. W. R., Waidmann, O., Klein, I., Lindig, U., Nadalin, S., Settmacher, U., Tacke, F., Schlitt, H. J., et al. (2021) · Zeitschrift für Gastroenterologie · doi:10.1055/a-1649-8643 · Cited by 5 · see citing works
Melanoma in Solid Organ Transplant Recipients
González‐Cruz, C., Ferrándiz‐Pulido, C., & García-Patos, V. (2021) · Actas Dermo-Sifiliográficas · doi:10.1016/j.adengl.2021.01.011 · Cited by 5 · see citing works
Skin Cancers and Lung Transplant
Wilken, R., Carucci, J. A., & Stevenson, M. L. (2021) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0041-1728798 · Cited by 5 · see citing works
Dai, T., Yang, Q., Zhang, Y., Ye, L., Li, H., Yi, S., Liu, W., Yang, Y., & Wang, G. (2021) · Liver Research · doi:10.1016/j.livres.2021.06.002 · Cited by 5 · see citing works
Cancer immunotherapy in patients with new or recurrent malignancies after liver transplantation
Liu, M., Guo, W., & Zhang, S. (2017) · International Journal of Surgery Oncology · doi:10.1097/ij9.0000000000000049 · Cited by 5 · see citing works
Immune Checkpoint Inhibitors and Liver Transplantation: Case Report and Review of the Literature
Skočilić, I., Košić, A., Badovinac, I., Kanižaj, T. F., Dobrila-Dintinjana, R., Kolak, M., Bukovica, A. M., Ropac, S., & Mikolašević, I. (2025) · Clinical Case Reports · doi:10.1002/ccr3.70412 · Cited by 2 · see citing works
Monneur, A., Monnier, J., Gaudy‐Marqueste, C., Devillier, R., & Sabatier, R. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.05.023 · Cited by 2 · see citing works
Anti-PD-1 Monotherapy Versus Anti-PD1 Plus Anti-CTLA4 in Advanced Melanoma: How do we Decide?
Au, L., O’Reilly, A., & Larkin, J. (2017) · Melanoma Management · doi:10.2217/mmt-2017-0016 · Cited by 2 · see citing works
Cutaneous Head and Neck Cancers in the High-Risk Immunosuppressed Population
Choi, K. Y., & Schmalbach, C. E. (2021) · Otolaryngologic Clinics of North America · doi:10.1016/j.otc.2020.11.012 · Cited by 2 · see citing works
Immune Checkpoint Inhibitors - New Insights and Recent Progress
Raza, A. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.100958 · Cited by 2 · see citing works
Toxicities in Immune Checkpoint Inhibitors
Lee, S. S., Loecher, M., & Puzanov, I. J. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-54948-6.00011-1 · Cited by 2 · see citing works
Bassil, C., & Khimani, F. (2020) · Journal of Onco-Nephrology · doi:10.1177/2399369320953163 · Cited by 2 · see citing works
- Authors
- Morales, R. E., Shoushtari, A. N., Walsh, M. M., Grewal, P., Lipson, E. J., & Carvajal, R. D.
- Affiliations
- Columbia University (US)
- Memorial Sloan Kettering Cancer Center (US)
- Columbia University Irving Medical Center (US)
- Icahn School of Medicine at Mount Sinai (US)
- Johns Hopkins University (US)
- Corresponding author
- Carvajal, Richard D
- Venue
- Journal for ImmunoTherapy of Cancer
- Publisher
- BMJ
- Published
- 2015-06-16
- Volume
- 3
- Issue
- 1
- Pages
- 22-22
- ISSN
- 2051-1426 (ISSN-L)
- PMC
- PMC4469313
- OpenAlex
- W1517732299
- Cited by
- 110
- References
- 12
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 6 · 2023: 9 · 2022: 11 · 2021: 12 · 2020: 10 · 2019: 9 · 2018: 13 · 2017: 21 · 2016: 13 · 2015: 2
- FWCI
- 7.13
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Journal for ImmunoTherapy of Cancer (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Columbia Academic Commons (Columbia University)
- Funders
- National Cancer Institute (P30CA008748)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- ipilimumab, liver transplantation, CTLA-4 blockade, cancer immunotherapy, solid organ transplant recipients, elevated liver enzymes, graft rejection, immunosuppression, treatment efficacy and safety
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
